[A Strategy of IL-6/IL-6R System Mediates Targeted Treatment for Leukemia]
An inevitable trend for the development of new treatment of leukemia is to use targeted strategy. IL-6/IL-6R is important one of the cytokine receptor targeted treatment systems. Many malignant cells, including multiple myeloma, prostate carcinoma and leukemia etc., have been shown to express IL-6R. Leukemia cells, especialy in U937, TF1, KG1 cell lines highly express the high affinity IL-6R. IL-6 recombinant toxin is cytotoxic in vitro to leukemia cell expressing high affinity IL-6R; in vivo the fusion toxin can result the reduction of leukemic cell load in animal leukemia model but have no effect on normal hematopoiesis in non-leukemic animal. On the basis of these pre-clinical studies, IL-6 recombinant toxin my become novel drug for the treatment of leukemia and cancer in future.
Cui
Jian-Wu
JW
Department of Immunology, Affiliated Hospital for Academy of Military Medical Sciences. Laboratory of Immunoassay, National Center of Biomedical Analysis, Beijing 100039, China.
Xi
Yong-Zhi
YZ